Display options
Cite
Dekker AD, Fortea J, Blesa R, et al. Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome. Alzheimers Dement (Amst). 2017;8:1-10doi: 10.1016/j.dadm.2017.02.006.
Dekker, A. D., Fortea, J., Blesa, R., & De Deyn, P. P. (2017). Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome. Alzheimer's & dementia (Amsterdam, Netherlands), 81-10. https://doi.org/10.1016/j.dadm.2017.02.006
Dekker, Alain D, et al. "Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 8 (2017): 1-10. doi: https://doi.org/10.1016/j.dadm.2017.02.006
Dekker AD, Fortea J, Blesa R, De Deyn PP. Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome. Alzheimers Dement (Amst). 2017 Mar 20;8:1-10. doi: 10.1016/j.dadm.2017.02.006. eCollection 2017. PMID: 28413821; PMCID: PMC5384293.
Copy Download .nbib Format: NLM
Share it on

Alzheimers Dement (Amst). 2017 Mar 20;8:1-10. doi: 10.1016/j.dadm.2017.02.006. eCollection 2017.

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome.

Alzheimer's & dementia (Amsterdam, Netherlands)

Alain D Dekker, Juan Fortea, Rafael Blesa, Peter P De Deyn

Affiliations

  1. Department of Neurology and Alzheimer Research Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  2. Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
  3. Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  4. Down Medical Center, Catalan Down Syndrome Foundation, Barcelona, Spain.

PMID: 28413821 PMCID: PMC5384293 DOI: 10.1016/j.dadm.2017.02.006

Abstract

Down syndrome (DS), present in nearly six million people, is associated with an extremely high risk to develop Alzheimer's disease (AD). Amyloid-β and tau pathology are omnipresent from age 40 years onward, but clinical symptoms do not appear in all DS individuals. Dementia diagnostics is complex in this population, illustrating the great need for predictive biomarkers. Although blood biomarkers have not yet proven useful, cerebrospinal fluid (CSF) biomarkers (low amyloid-β42, high t-tau, and high p-tau) effectively contribute to AD diagnoses in the general population and are increasingly used in clinical practice. Surprisingly, CSF biomarkers have been barely evaluated in DS. Breaking the taboo on CSF analyses would finally allow for the elucidation of its utility in (differential) diagnoses and staging of disease severity. A sensitive and specific biomarker profile for AD in DS would be of paramount importance to daily care, adaptive caregiving, and specific therapeutic interventions.

Keywords: Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Dementia; Down syndrome

References

  1. Cortex. 2015 Dec;73:36-61 - PubMed
  2. Transl Psychiatry. 2014 Aug 12;4:e425 - PubMed
  3. Alzheimers Dement. 2016 Nov;12(11):1132-1148 - PubMed
  4. Nat Rev Neurol. 2015 Oct;11(10):549-50 - PubMed
  5. Curr Gerontol Geriatr Res. 2012;2012:170276 - PubMed
  6. J Alzheimers Dis. 2015;45(3):733-43 - PubMed
  7. J Intellect Disabil. 2014 Dec;18(4):305-14 - PubMed
  8. Alzheimers Dement. 2015 May;11(5):523-32 - PubMed
  9. Neurobiol Aging. 2008 Aug;29(8):1143-59 - PubMed
  10. Neurobiol Dis. 1996 Feb;3(1):16-32 - PubMed
  11. Nat Rev Neurosci. 2015 Sep;16(9):564-74 - PubMed
  12. J Alzheimers Dis. 2014;42(1):157-67 - PubMed
  13. J Alzheimers Dis. 2014;42(3):767-75 - PubMed
  14. Alzheimers Dement. 2016 Apr;12(4):459-509 - PubMed
  15. Eur J Public Health. 2007 Apr;17(2):221-5 - PubMed
  16. Alzheimers Dement. 2015 Jun;11(6):700-9 - PubMed
  17. Ann Neurol. 1998 Mar;43(3):380-3 - PubMed
  18. Eur J Neurol. 2010 Oct;17(10):1236-48 - PubMed
  19. J Intellect Disabil Res. 2000 Dec;44 ( Pt 6):654-65 - PubMed
  20. J Intellect Disabil Res. 2008 Apr;52(Pt 4):358-68 - PubMed
  21. J Alzheimers Dis. 2014;39(4):719-26 - PubMed
  22. Histopathology. 1988 Aug;13(2):125-37 - PubMed
  23. Brain. 2015 Sep;138(Pt 9):2716-31 - PubMed
  24. Neuromolecular Med. 2014 Jun;16(2):510-6 - PubMed
  25. J Ment Defic Res. 1987 Sep;31 ( Pt 3):259-69 - PubMed
  26. BMC Neurol. 2014 Dec 31;14:254 - PubMed
  27. Ann Neurol. 1999 Dec;46(6):933 - PubMed
  28. Cochrane Database Syst Rev. 2015 Oct 29;(10):CD011546 - PubMed
  29. Alzheimers Dement. 2014 Jul;10(4):448-455.e2 - PubMed
  30. Alzheimers Dement. 2012 Jul;8(4):312-36 - PubMed
  31. Alzheimers Dement. 2011 May;7(3):257-62 - PubMed
  32. Neurobiol Aging. 2012 Sep;33(9):1988-94 - PubMed
  33. Neurosci Biobehav Rev. 2014 Sep;45:72-84 - PubMed
  34. Nature. 2016 Aug 31;537(7618):50-6 - PubMed
  35. Dement Geriatr Cogn Disord. 2007;24(5):369-74 - PubMed
  36. J Alzheimers Dis. 2017;55(4):1489-1496 - PubMed
  37. Am J Hum Biol. 2003 Mar-Apr;15(2):192-5 - PubMed
  38. Neurobiol Aging. 1998 Jul-Aug;19(4):307-9 - PubMed
  39. Neurochem Int. 2009 Dec;55(8):820-5 - PubMed
  40. Clin Neurol Neurosurg. 2005 Apr;107(3):165-73 - PubMed
  41. Acta Neurol Scand. 1984 May;69(5):302-5 - PubMed
  42. J Neuropathol Exp Neurol. 2007 Apr;66(4):264-71 - PubMed
  43. Alzheimers Dement. 2016 Feb;12(2):154-163 - PubMed
  44. Front Behav Neurosci. 2015 Sep 14;9:239 - PubMed
  45. Brain. 2016 Apr;139(Pt 4):1226-36 - PubMed
  46. Neurology. 2001 Apr 10;56(7):979-80 - PubMed
  47. J Proteome Res. 2006 Apr;5(4):1010-6 - PubMed
  48. J Alzheimers Dis. 2015;43(3):871-91 - PubMed
  49. Neurology. 1998 Jan;50(1):169-74 - PubMed
  50. Neurodegener Dis. 2014;14(2):98-106 - PubMed
  51. Ann Neurol. 1987 Apr;21(4):408-11 - PubMed
  52. Neurology. 2012 Jan 3;78(1):47-54 - PubMed
  53. Curr Alzheimer Res. 2009 Jun;6(3):290-2 - PubMed
  54. Alzheimers Dement. 2015 Jan;11(1):58-69 - PubMed
  55. J Clin Neurol. 2016 Oct;12(4):381-392 - PubMed
  56. Alzheimers Dement. 2011 May;7(3):263-9 - PubMed
  57. Lancet Neurol. 2016 May;15(6):622-36 - PubMed
  58. Clin Chem. 2015 May;61(5):734-43 - PubMed
  59. Intellect Dev Disabil. 2008 Jun;46(3):215-28 - PubMed

Publication Types